The FBI has issued a major warning (Alert I-022825-PSA, Feb 28, 2025) about fraudulent compounding practices involving semaglutide, the active ingredient in Ozempic and Wegovy. This alert is critical for medspa owners, weight loss clinics, and pharmacies—especially those involved in medical weight loss programs.
What’s the Warning About?
According to the FBI, noncompliant healthcare providers—including pharmacies, medspas, and weight loss clinics—have been selling fraudulently compounded semaglutide with misleading claims about its ingredients and safety.
🔹 Some compounds tested contained NO semaglutide at all
🔹 Others had high levels of unknown drug impurities
🔹 One clinic was using “animal grade” semaglutide mixed with B12—a clear FDA violation
🔹 A pharmacy in the Southeast filled over 1,000 prescriptions daily, selling high-dose semaglutide with vitamin B6 and making millions before being shut down
Who Does This Impact?
If you run a medspa, weight loss clinic, or pharmacy that offers compounded semaglutide, this warning is for you. Clinics sourcing from compounding pharmacies must vet their suppliers carefully to avoid liability and protect patient safety.
What Are the Risks?
The FBI warns that these misrepresented drugs could cause serious health issues, including:
⚠️ Gastrointestinal disorders
⚠️ Nervous system disorders
⚠️ Cardiac complications
⚠️ Psychiatric issues
⚠️ Even death in severe cases
What Should You Do?
✅ Only source semaglutide from reputable, FDA-compliant compounding pharmacies
✅ Be wary of unusually low prices—if it seems too good to be true, it probably is
✅ Educate patients about the risks of improperly compounded weight loss drugs
✅ Report any suspicious activity to the FBI’s Internet Crime Complaint Center (ic3.gov) and the FDA’s MedWatch program
Read the Full FBI Alert Here:
👉 FBI Public Service Announcement
The weight loss boom has brought both opportunity and risk to the medspa industry. Ensuring patient safety and regulatory compliance is key to protecting your business—and your clients.
